New obesity drug shows promise in energy burn test
NCT ID NCT06745284
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests a new medicine called survodutide to see if it helps people with obesity burn more energy and fat. About 64 adults aged 18 to 65 with a BMI between 30 and 45 will take part. They will receive either survodutide or the existing drug semaglutide once a week for several months. Researchers will measure energy use in a special room to compare the two treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth - Translation Research Institute
Orlando, Florida, 32804, United States
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
Conditions
Explore the condition pages connected to this study.